Short Interest in TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Expands By 474.1%

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 181,400 shares, an increase of 474.1% from the December 31st total of 31,600 shares. Based on an average daily trading volume, of 2,260,000 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright decreased their target price on shares of TC Biopharm from $5.60 to $2.40 and set a “buy” rating on the stock in a research report on Friday, December 6th.

TC Biopharm Price Performance

Shares of NASDAQ:TCBP traded down $0.02 during midday trading on Tuesday, reaching $0.28. The company’s stock had a trading volume of 399,167 shares, compared to its average volume of 873,940. The business has a 50 day moving average price of $0.46 and a 200 day moving average price of $2.73. TC Biopharm has a 1 year low of $0.25 and a 1 year high of $26.16.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.